Through our highly experienced ADC Research & Development Team, we are building a pipeline of class-leading ADCs with superior therapeutic index (TI) for difficult-to-treat cancers.
Our approach is to develop the best ADC for any given target or tumor sub-type rather than 'technology-driven ADCs'.
All our ADCs incorporate tumor-selective release & activation of the most relevant payload according to mechanism, optimizing anti-cancer efficacy and enhancing patient safety.
Company Details
- Employees
- 44
- Address
- The Biosphere, Draymans Way, Newcastle Helix,united Kingdom
- Phone
- +44 0191 6031680
- in****@****uda.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- glythera.com
- Keywords
- Antibody-Drug Conjugates, PermaLink™, Conjugation Chemistry, Cancer research, ADCs, Drug Development, Therapeutics, Antibodies, Toxins, Cancer Treatment, ADC Stability, Antibody Drug Conjugate, Drug Discovery, Biotechnology, Preclinical, Bioconjugation, Organic Synthesis, Clinical, Cell Biology, Chemistry, Licencing.
- HQ
- Newcastle Upon Tyne, Tyne and Wear
Iksuda Therapeutics Questions
Iksuda Therapeutics's helpline number is +44 0191 6031680
Iksuda Therapeutics's website is glythera.com
Iksuda Therapeutics's LinkedIn profile is https://uk.linkedin.com/company/iksudatherapeutics
Iksuda Therapeutics has
44 employees.
View email and phone details for 44
employees at Iksuda Therapeutics.
Iksuda Therapeutics's industry is
Biotechnology Research
Iksuda Therapeutics's top competitors are
Nanovery,
Alcyomics,
Magnitude Biosciences Ltd,
Nunabio Limited,
Cellrev,
3d Bio-Tissues,
Atelerix Ltd.,
The Biosphere,
Mdna Life Sciences,
Newcells Biotech Ltd.
Iksuda Therapeutics's support email address is info@iksuda.com
Iksuda Therapeutics's categories are Biotechnology Research
